Tag
50 posts tagged “Lose fat”.
A measured, harm-reduction look at orforglipron, a non-peptide GLP-1 pill approved for obesity, and what actually matters to track.
A neutral, harm-reduction guide to the oral semaglutide weight-management pill, its strict dosing rules, and what to monitor.
A harm-reduction look at CagriSema, an investigational amylin-plus-GLP-1 combination not yet approved, and what would be worth tracking.
A neutral, harm-reduction guide to mazdutide, a dual glucagon/GLP-1 agonist approved in China, and what to monitor.
A harm-reduction look at survodutide, an investigational GLP-1/glucagon agonist with obesity and MASH data, not yet approved.
A candid, harm-reduction look at cardarine, its endurance and fat-oxidation effects, and the rodent carcinogenicity signal that ended its development.
A neutral, harm-reduction guide to amycretin, an investigational GLP-1/amylin agonist in oral and injectable forms, entering Phase 3.
A harm-reduction look at andarine, its use in cutting phases, and the reversible vision side effect that sets it apart from other SARMs.
A harm-reduction look at VK2735, an investigational GIP/GLP-1 agonist in oral and injectable Phase 3 programs, not yet approved.
A neutral, harm-reduction guide to pemvidutide, an investigational GLP-1/glucagon agonist noted for lean-mass sparing and MASH data.
A harm-reduction look at SR9009, its exercise-mimetic claims, and the poor oral bioavailability that undercuts most real-world use.
A harm-reduction look at bimagrumab, an investigational antibody that lowers fat while preserving or adding muscle, studied with semaglutide.
A cautious, harm-reduction look at clenbuterol, a stimulant thermogenic with real cardiac risk, and what to monitor if you have already decided to use it.
A measured look at liothyronine (T3), why it is used for fat loss, and the muscle and cardiac risks that come with suppressing your own thyroid.
A blunt harm-reduction guide to DNP, a mitochondrial uncoupler with a narrow margin between fat loss and death, for people who have already obtained it.
A measured, harm-reduction look at testosterone enanthate, what to monitor on TRT or a cycle, and the bloodwork that actually matters.
Cypionate behaves almost identically to enanthate. Here is what to monitor, the bloodwork that matters, and the mistakes to avoid.
Propionate clears fast, which means frequent injections and sharper fluctuations. Here is what that changes about tracking.
A four-ester testosterone blend with a tricky release curve. Why the mixed esters complicate tracking and what to monitor.
A potent 19-nor anabolic with a heavy side-effect load. This is a harm-reduction tracking guide, not an endorsement.
Same potent, high-risk compound as the enanthate version, on a short ester. What the faster clearance changes for tracking.
A DHT-derived anabolic associated with cutting and "hardening." What that means, what it does not do, and what to monitor.
The longer-acting version of Masteron. Same DHT-derived profile, fewer injections, slower kinetics. What to track.
Often called gentle, but still suppressive and not risk-free. What "mild" actually means and what to monitor.
An oral with a real medical history and a gentle reputation - but real liver, lipid, and suppression concerns. What to monitor.
A DHT-derived steroid known for a "dry" look - and for hammering cholesterol and joints. What to monitor closely.
What 5-Amino-1MQ is, why it is studied as a metabolic compound, and how a self-experimenter can structure tracking around very limited human data.
A practical tracking guide for the DAC version of CJC-1295, with weekly dosing rationale and IGF-1 expectations.
A pragmatic log structure for ipamorelin used on its own, separate from the common CJC-1295 stack.
How the short-acting GHRH analog works, why it mimics natural GH pulses, and what to track when using it.
What AOD-9604 is, why it failed in obesity trials, and how to track fat-loss protocols if you choose to use it.
What to know about using a pre-mixed CJC-1295/ipamorelin blend versus separate vials, and how it affects your tracking.
A tracking guide for metformin that takes its prescription status and side effects seriously.
Weekly GLP-1 receptor agonist with a clean titration shape — what to track and how it compares to semaglutide and tirzepatide.
A tracking guide for sermorelin, the 29-amino-acid GHRH analog, with realistic expectations for sleep, recovery, and IGF-1 changes.
What MOTS-c does, what it might do in humans, and how to track it honestly.
A focused guide to tracking a tirzepatide protocol — the titration, the unique GIP-side effects, sulfur burps, and what to log week-over-week.
A practical look at pre-mixed sermorelin/ipamorelin blends — the GHRH plus GHRP rationale and the tracking tradeoffs of using one syringe.
A pragmatic guide to logging a semaglutide titration. What to capture daily, weekly, and at every dose increase.
The first-in-class GLP-1 receptor agonist, derived from Gila monster venom — twice-daily and weekly versions tracked.
How to log L-carnitine use across oral, injectable, and IV protocols with realistic expectations.
A careful tracking guide for recombinant human growth hormone, focused on what to monitor when using a prescription compound with real metabolic consequences.
A practical tracking guide for GHRP-2, a ghrelin mimetic often paired with GHRH analogs, with attention to cortisol and prolactin.
What cagrilintide is, why it is being studied with semaglutide as CagriSema, and how to track appetite, weight, and tolerability.
How to log a liraglutide titration and decide whether the daily-injection tradeoff makes sense for you.
What Retatrutide is, how the GLP-1 / GIP / glucagon mechanism differs from single-agonists, and how to track titration and side effects honestly.
Two growth-hormone-releasing peptides that are usually used together. How they differ, how protocols are structured, and what to track.
The two leading GLP-1 protocols compared by what they ask of the user, what to track, and how the side-effect profiles differ across a titration.
What tesamorelin is, how protocols are structured, what to measure if you want to evaluate effects on visceral fat, energy, and sleep.
What HGH fragment 176-191 is, why protocols are structured the way they are, and the daily/weekly metrics that actually reveal whether it works for you.